Competence Center for Methodology and Statistics, Luxembourg Institute of Health, Strassen, Luxembourg.
Competence Center for Methodology and Statistics, Luxembourg Institute of Health, Strassen, Luxembourg; Zortify, Luxembourg City, Luxembourg.
Lancet Microbe. 2024 Apr;5(4):e366-e378. doi: 10.1016/S2666-5247(23)00377-4. Epub 2024 Mar 9.
Accurate diagnosis is pivotal for implementing strategies for surveillance, control, and elimination of schistosomiasis. Despite their low sensitivity in low-endemicity areas, microscopy-based urine filtration and the Kato-Katz technique are considered as reference diagnostic tests for Schistosoma haematobium and Schistosoma mansoni infections, respectively. We aimed to collate all available evidence on the accuracy of other proposed diagnostic techniques.
In this systematic review and meta-analysis, we searched PubMed, Embase, the Cochrane Library, and LILACS for studies published from database inception to Dec 31, 2022, investigating the sensitivity and specificity of diagnostic tests for S haematobium and S mansoni infections against Kato-Katz thick smears or urine microscopy (reference tests) involving adults (aged ≥18 years), school-aged children (aged 7 to 18 years), or preschool-aged children (aged 1 month to 7 years). We extracted raw data on true positives, true negatives, false positives, and false negatives for the diagnostic tests and data on the number of participants, study authors, publication year, journal, study design, participants' age and sex, prevalence of Schistosoma infection, and treatment status. To account for imperfect reference tests, we used a hierarchical Bayesian latent class meta-analysis to model test accuracy.
Overall, we included 121 studies, assessing 28 different diagnostic techniques. Most studies (103 [85%] of 121) were done in Africa, 14 (12%) in South America, one (1%) in Asia, and one (1%) in an unknown country. Compared with the reference test, Kato-Katz thick smears, circulating cathodic antigen urine cassette assay version 1 (CCA1, 36 test comparisons) had excellent sensitivity (95% [95% credible interval 88-99]) and reasonable specificity (74% [63-83]) for S mansoni. ELISA-based tests had a performance comparable to circulating cathodic antigen, but there were few available test comparisons. For S haematobium, proteinuria (42 test comparisons, sensitivity 73% [62-82]; specificity 94% [89-98]) and haematuria (75 test comparisons, sensitivity 85% [80-90]; specificity 96% [92-99]) reagent strips showed high specificity, with haematuria reagent strips having better sensitivity. Despite limited data, nucleic acid amplification tests (NAATs; eg, PCR or loop-mediated isothermal amplification [LAMP]) showed promising results with sensitivity estimates above 90%. We found an unclear risk of bias of about 70% in the use of the reference or index tests and of 50% in patient selection. All analyses showed substantial heterogeneity (I>80%).
Although NAATs and immunological diagnostics show promise, the limited information available precludes drawing definitive conclusions. Additional research on diagnostic accuracy and cost-effectiveness is needed before the replacement of conventional tests can be considered.
WHO and Luxembourg Institute of Health.
准确的诊断对于实施血吸虫病的监测、控制和消除策略至关重要。尽管在低流行地区的灵敏度较低,但基于显微镜的尿液过滤和加藤厚涂片检查技术分别被认为是检测埃及血吸虫和曼氏血吸虫感染的参考诊断测试。我们旨在汇总所有关于其他拟议诊断技术准确性的可用证据。
在本系统评价和荟萃分析中,我们检索了从数据库建立到 2022 年 12 月 31 日发表的研究,调查了针对埃及血吸虫和曼氏血吸虫感染的诊断测试的灵敏度和特异性,这些测试针对加藤厚涂片检查或尿液显微镜检查(参考测试),涉及成年人(年龄≥18 岁)、学龄儿童(年龄 7 至 18 岁)或学龄前儿童(年龄 1 个月至 7 岁)。我们提取了诊断测试的真实阳性、真实阴性、假阳性和假阴性的原始数据,以及参与者数量、研究作者、出版年份、期刊、研究设计、参与者年龄和性别、血吸虫感染流行率和治疗状况的数据。为了考虑参考测试的不完美性,我们使用分层贝叶斯潜在类别荟萃分析来模拟测试准确性。
总体而言,我们纳入了 121 项研究,评估了 28 种不同的诊断技术。大多数研究(121 项中的 103 项)在非洲进行,14 项(12%)在南美洲,1 项(1%)在亚洲,1 项(1%)在未知国家。与参考测试相比,加藤厚涂片检查和循环阴沟血抗原尿盒检测 1 版(CCA1,36 次测试比较)对曼氏血吸虫具有出色的灵敏度(95%[95%置信区间 88-99%])和合理的特异性(74%[63-83%])。基于 ELISA 的测试具有与循环阴沟血抗原相当的性能,但可用的测试比较很少。对于埃及血吸虫,蛋白尿(42 次测试比较,灵敏度 73%[62-82%];特异性 94%[89-98%])和血尿(75 次测试比较,灵敏度 85%[80-90%];特异性 96%[92-99%])试剂条显示出高特异性,血尿试剂条具有更好的灵敏度。尽管数据有限,但核酸扩增测试(如 PCR 或环介导等温扩增 [LAMP])的灵敏度估计值超过 90%,显示出有希望的结果。我们发现参考或索引测试和患者选择的偏倚风险约为 70%和 50%,存在不确定因素。所有分析均显示存在高度异质性(I>80%)。
尽管核酸扩增测试和免疫诊断具有前景,但现有信息有限,无法得出明确结论。在考虑替代传统测试之前,需要进行更多关于诊断准确性和成本效益的研究。
世卫组织和卢森堡健康研究所。